Development of therapeutic antibodies for the treatment of diseases
Top Cited Papers
Open Access
- 2 January 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Biomedical Science
- Vol. 27 (1), 1-30
- https://doi.org/10.1186/s12929-019-0592-z
Abstract
It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to their high specificity. As a result, therapeutic antibodies have become the predominant class of new drugs developed in recent years. Over the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2018, eight of the top ten bestselling drugs worldwide were biologics. The global therapeutic monoclonal antibody market was valued at approximately US$115.2 billion in 2018 and is expected to generate revenue of $150 billion by the end of 2019 and $300 billion by 2025. Thus, the market for therapeutic antibody drugs has experienced explosive growth as new drugs have been approved for treating various human diseases, including many cancers, autoimmune, metabolic and infectious diseases. As of December 2019, 79 therapeutic mAbs have been approved by the US FDA, but there is still significant growth potential. This review summarizes the latest market trends and outlines the preeminent antibody engineering technologies used in the development of therapeutic antibody drugs, such as humanization of monoclonal antibodies, phage display, the human antibody mouse, single B cell antibody technology, and affinity maturation. Finally, future applications and perspectives are also discussed.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (106-0210-01-15-02, 107-0210-01-19-01, 107-0210-01-19-04)
This publication has 260 references indexed in Scilit:
- Monoclonal antibody humanness score and its applicationsBMC Biotechnology, 2013
- Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerizationVaccine, 2012
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- The Humanness of Macaque Antibody SequencesJournal of Molecular Biology, 2010
- Phage-display selection on tumor histological specimens with laser capture microdissectionJournal of Immunological Methods, 2009
- A method for identification of HIV gp140 binding memory B cells in human bloodJournal of Immunological Methods, 2009
- Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?Published by Springer Science and Business Media LLC ,2008
- The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity AntibodiesJournal of Molecular Biology, 2008
- Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloningJournal of Immunological Methods, 2008
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986